Ignite Creation Date:
2024-05-06 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05335720
Status:
COMPLETED
Last Update Posted:
2022-07-22
First Post:
2022-04-06
Brief Title:
Efficacy and Safety Evaluation of EASYEF in Acute Wound Split-thickness Skin Graft Donor Site
Sponsor:
PT Daewoong Infion
Organization:
PT Daewoong Infion
Study Overview
Official Title:
Study to Evaluate the Efficacy and Safety of EASYEF in Acute Wound Split-thickness Skin Graft Donor Site
Status:
COMPLETED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a prospective study randomized using control open-label single-center to evaluate the efficacy and safety of EASYEF in acute wound split-thickness skin graft donor site A total of 10 subjects are randomly allocated Subjects who meet the final inclusion and exclusion criteria are randomized to the test cohorts in a ratio of 111
Detailed Description:
This study was intended to determine the effect of EGF on acute wounds such as trauma surgical wounds and burns But in this study skin graft donor site wounds were used because they were the most representative for acute wounds and the depth and extent of the wounds could be controlled EGF is known pharmacologically to accelerate epithelial cell proliferation fibroblast cells and endothelial cells Giving EGF in acute wounds is expected to accelerate wound healing and improve patient quality of life
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None